Thanmay Sai Charaan Reddy Sathi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thanmay Sai Charaan Reddy Sathi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Amena Firoz
Pediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
1 shared publication - Barun Ray
Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, NPL
1 shared publication - Bibek Dhungana
Internal Medicine, KIST Medical College, Lalitpur, NPL
1 shared publication Bibek Kc
Internal Medicine, KIST Medical College, Lalitpur, NPL
1 shared publication- Deepak Verma
Janaki Medical College, Dhanusha, Nepal 8
1 shared publication - Gunjan Shah
Internal Medicine, Janaki Medical College, Janakpurdham, NPL
1 shared publication
Latest Publications
- Open Access
- 17 August 2021
- Published by Springer Nature in Cureus
- Vol. 13 (8)
Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management
Cardiorenal syndrome refers to combined cardiac and renal dysfunction that adversely impacts both organs and is also associated with severe clinical outcomes. The pathophysiology is believed to be multifactorial and complex. Increased central venous pressure and intra-abdominal pressure, overactivation of the Renin-Angiotensin-Aldosterone System (RAAS), systemic illnesses like sepsis, amyloidosis, diabetes are important factors in developing the cardiorenal syndrome. Our review article attempts to review the pathophysiology and treatment aspect of cardiorenal syndrome and explores potential therapeutic strategies that can be adopted for the management. We searched PubMed, EMBASE, Google Scholar for relevant articles using different keywords and Medical Subject Headings, and finalized 38 articles to be included in our study. Cardiorenal syndrome management aims to eliminate venous congestion and fluid retention, which leads to improved cardiorenal status. This is usually achieved using pharmacologic agents like diuretics, vasodilators, inotropes, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs), neprilysin inhibitors, and extracorporeal methods like ultrafiltration. The use of therapeutic agents such as sodium-glucose co-transporter 2 inhibitors and tolvaptan (a vasopressin V2 receptor antagonist), and cardiac resynchronization therapy has also been shown to have potential benefits in managing the disease. These agents can be instrumental in the management and require large-scale clinical trials specifically aimed at improving cardiorenal outcomes based on severity and type of cardiorenal syndrome.
- 17 August 2021
- Published by Springer Nature in Cureus
- Vol. 13 (8)
Open AccessEmerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management
Cardiorenal syndrome refers to combined cardiac and renal dysfunction that adversely impacts both organs and is also associated with severe clinical outcomes. The pathophysiology is believed to be multifactorial and complex. Increased central venous pressure and intra-abdominal pressure, overactivation of the Renin-Angiotensin-Aldosterone System (RAAS), systemic illnesses like sepsis, amyloidosis, diabetes are important factors in developing the cardiorenal syndrome. Our review article attempts to review the pathophysiology and treatment aspect of cardiorenal syndrome and explores potential therapeutic strategies that can be adopted for the management. We searched PubMed, EMBASE, Google Scholar for relevant articles using different keywords and Medical Subject Headings, and finalized 38 articles to be included in our study. Cardiorenal syndrome management aims to eliminate venous congestion and fluid retention, which leads to improved cardiorenal status. This is usually achieved using pharmacologic agents like diuretics, vasodilators, inotropes, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs), neprilysin inhibitors, and extracorporeal methods like ultrafiltration. The use of therapeutic agents such as sodium-glucose co-transporter 2 inhibitors and tolvaptan (a vasopressin V2 receptor antagonist), and cardiac resynchronization therapy has also been shown to have potential benefits in managing the disease. These agents can be instrumental in the management and require large-scale clinical trials specifically aimed at improving cardiorenal outcomes based on severity and type of cardiorenal syndrome.